By 2030, more than 350,000 patients will be able to treat with advanced treatments. But new financing models are needed to support expenses and investmentsby Barbara GobbiApril 22, 2021(imagoeconomica)(imagoeconomica)The key points
2030 target for 60 cutting-edge therapiesThe resource nodeFinancing therapies as weapons are financed4 ‘of readingThe lesson came loud and clear from the pandemic: health and healthcare must be viewed as an investment, under penalty of seeing a country-system or the economic-financial assets of an entire planet collapse.
And the lesson also covers many serious diseases that will remain when we have tamed the coronavirus. Cancers, rare, autoimmune and infectious diseases afflict millions of individuals and jeopardize the sustainability of the NHS.
Today we are at a turning point, made possible by the massive arrival of highly innovative advanced therapies, which will be available to patients in the next few years. It is certain and sacrosanct that the sick demand them: the prospect of healing with a “one shot” intervention will open up scenarios that can already be glimpsed with the positive experiences of Car T for tumors.
However, innovative treatments have very high costs and to make them sustainable there is a proposal to redevelop current expenses at investment costs. The Ministry of Health and the Mef are working on it:
“Advanced therapies represent a unique potential for treatment in which it is important to invest, both for the health system and for the country – explains Undersecretary of Health Pierpaolo Sileri -.
The synergy at the political and technical, national and European level, will be crucial to identify organizational and financing models that guarantee full uniformity in the access to these treatments, in compliance with the principles of equity, universality and sustainability “.2030 target for 60 cutting-edge therapies
The target set as the first “mass” arrival of gene therapies is 2030: 16 thousand are being tested and sixty will arrive by the end of the decade, capable of treating over 350 thousand patients, with an increase of 50 thousand a year.
Over 450 pharmaceutical companies around the world are working on it – for a total of 900 companies engaged in the wide audience of advanced therapies – and it is this, together with the research on mRna treatments that came to the fore with Covid vaccines, one of the first bets of world research.
The resource node
The turning point will be not only for the individual, but for the entire society which will be relieved of the direct and indirect costs of diseases that are currently very heavy from the point of view of assistance, drugs, loss of productivity, social security and careving. But for this clear change of pace to be possible, massive resources are needed and – indeed – the choice of accounting for expenditure as an investment. ”
Let’s take a thalassemia patient: the cost of a” standard “treatment for the National Health Service is around 2.4 million: assuming a treatment with gene therapy from 15 years of age, we estimate a saving of 600 thousand euros over the life, to which add at least 300 thousand lower costs attributable to welfare.
So just for this patient, with advanced therapy we would reduce the costs by a third ». Speaking is Americo Cicchetti, professor of business organization at the Catholic University and director of Altems, who spoke at the conference ”
Advanced therapies: how to reach a sustainable paradigm change”, organized by Fortune Italia with the Parliamentary Intergroup Science and Health, CittadinanzAttiva and the association #VITA (Value and Innovation of advanced therapies). ”
We carried out an impact analysis – explains Cicchetti – elaborating a first estimate according to which these treatments, based on the type of penetration they will have on the market, in 2022 will lead to an increase in NHS spending between 400 million euros and 2 billion only in Italy.
With an intermediate expenditure forecast of one billion, the estimated saving for 2022 alone is around 400 million, reducing the actual expenditure for that single patient to 600 million.
More: the model we are developing – based on four advanced therapies applied to two types of cancer, thalassemia and haemophilia – estimates a net ‘neutral’ effect of the theoretical billion spent in 2022 over a time horizon of 40 years.
I will make up for everything that I have spent in that year in the next 40 years, because I will have cut down the costs of assistance which have failed with the definitive recovery from a certain disease. “” The development of advanced therapies plays a fundamental role in the treatment and in the prevention of various pathologies: from haemophilia
A and B to Parkinson’s, from spinal muscular atrophy to Duchenne muscular dystrophy, passing through thalassemia and mutations associated with retinal dystrophy. But there are many others – adds Angela Ianaro, president of the Science and Innovation Parliamentary Intergroup -.
Faced with this revolutionary technology, institutions, patient associations and industry must work together to find courageous and innovative solutions that guarantee universal access to innovation, preventing accounting conventions and rationing needs from becoming an obstacle ».